Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1995 Feb;48(2):129–132. doi: 10.1136/jcp.48.2.129

c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus.

R H Hardwick 1, N A Shepherd 1, M Moorghen 1, P V Newcomb 1, D Alderson 1
PMCID: PMC502378  PMID: 7745111

Abstract

AIMS--To investigate overexpression of the oncoprotein c-erbB-2 in the dysplasia/carcinoma sequence of Barrett's columnar-lined oesophagus (CLO). METHODS--Immunohistochemical staining was performed using the monoclonal antibody NCL-CB-11 on formalin fixed tissue from 31 cases of Barrett's carcinoma, 20 cases of cancer associated dysplastic CLO, seven cases of dysplastic CLO without cancer, and 20 cases of non-dysplastic CLO. Membranous staining was regarded as positive for c-erbB-2 overexpression; cytoplasmic staining was recorded separately as its significance is uncertain. RESULTS--Membranous c-erbB-2 overexpression was observed in eight of 31 (26%) carcinomas and in none of the cases of dysplastic CLO. Variable cytoplasmic staining was seen in four of 31 (13%) tumours and seven of 27 (26%) cases of dysplastic CLO. No staining was observed in non-dysplastic CLO. CONCLUSIONS--C-erbB-2 overexpression is a relatively late event in the development of some Barrett's carcinomas and is unlikely to be involved in the early stages of neoplastic transformation of CLO.

Full text

PDF
132

Images in this article

130Image
on p.130
130Image
on p.130

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akiyama T., Sudo C., Ogawara H., Toyoshima K., Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986 Jun 27;232(4758):1644–1646. doi: 10.1126/science.3012781. [DOI] [PubMed] [Google Scholar]
  2. Bargmann C. I., Hung M. C., Weinberg R. A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell. 1986 Jun 6;45(5):649–657. doi: 10.1016/0092-8674(86)90779-8. [DOI] [PubMed] [Google Scholar]
  3. Chiu K. Y., Loke S. L., Ho F. C. Immunohistochemical demonstration of c-erbB-2 oncoprotein in gastric adenocarcinoma: comparison of cryostat and paraffin wax sections and effect of fixation. J Clin Pathol. 1994 Feb;47(2):117–121. doi: 10.1136/jcp.47.2.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Coombs L. M., Oliver S., Sweeney E., Knowles M. Immunocytochemical localization of c-erbB-2 protein in transitional cell carcinoma of the urinary bladder. J Pathol. 1993 Jan;169(1):35–42. doi: 10.1002/path.1711690107. [DOI] [PubMed] [Google Scholar]
  5. Coombs L. M., Pigott D. A., Sweeney E., Proctor A. J., Eydmann M. E., Parkinson C., Knowles M. A. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer. 1991 Apr;63(4):601–608. doi: 10.1038/bjc.1991.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Corbett I. P., Henry J. A., Angus B., Watchorn C. J., Wilkinson L., Hennessy C., Gullick W. J., Tuzi N. L., May F. E., Westley B. R. NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol. 1990 May;161(1):15–25. doi: 10.1002/path.1711610105. [DOI] [PubMed] [Google Scholar]
  7. D'Emilia J., Bulovas K., D'Ercole K., Wolf B., Steele G., Jr, Summerhayes I. C. Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene. 1989 Oct;4(10):1233–1239. [PubMed] [Google Scholar]
  8. De Potter C. R., Quatacker J., Maertens G., Van Daele S., Pauwels C., Verhofstede C., Eechaute W., Roels H. The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer. 1989 Dec 15;44(6):969–974. doi: 10.1002/ijc.2910440604. [DOI] [PubMed] [Google Scholar]
  9. Di Fiore P. P., Pierce J. H., Kraus M. H., Segatto O., King C. R., Aaronson S. A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987 Jul 10;237(4811):178–182. doi: 10.1126/science.2885917. [DOI] [PubMed] [Google Scholar]
  10. Fléjou J. F., Paraf F., Muzeau F., Fékété F., Hénin D., Jothy S., Potet F. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. J Clin Pathol. 1994 Jan;47(1):23–26. doi: 10.1136/jcp.47.1.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hameeteman W., Tytgat G. N., Houthoff H. J., van den Tweel J. G. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology. 1989 May;96(5 Pt 1):1249–1256. doi: 10.1016/s0016-5085(89)80011-3. [DOI] [PubMed] [Google Scholar]
  12. Hamilton S. R., Smith R. R., Cameron J. L. Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. Hum Pathol. 1988 Aug;19(8):942–948. doi: 10.1016/s0046-8177(88)80010-8. [DOI] [PubMed] [Google Scholar]
  13. Hardwick R. H., Shepherd N. A., Moorghen M., Newcomb P. V., Alderson D. Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut. 1994 Jun;35(6):764–768. doi: 10.1136/gut.35.6.764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Holmes W. E., Sliwkowski M. X., Akita R. W., Henzel W. J., Lee J., Park J. W., Yansura D., Abadi N., Raab H., Lewis G. D. Identification of heregulin, a specific activator of p185erbB2. Science. 1992 May 22;256(5060):1205–1210. doi: 10.1126/science.256.5060.1205. [DOI] [PubMed] [Google Scholar]
  15. Jankowski J., Coghill G., Hopwood D., Wormsley K. G. Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut. 1992 Aug;33(8):1033–1038. doi: 10.1136/gut.33.8.1033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kamel D., Päkkö P., Nuorva K., Vähäkangas K., Soini Y. p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. J Pathol. 1993 May;170(1):67–72. doi: 10.1002/path.1711700111. [DOI] [PubMed] [Google Scholar]
  17. Miros M., Kerlin P., Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut. 1991 Dec;32(12):1441–1446. doi: 10.1136/gut.32.12.1441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ohguri T., Sato Y., Koizumi W., Saigenji K., Kameya T. An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erbB-2 protein really a prognostic indicator? Int J Cancer. 1993 Jan 2;53(1):75–79. doi: 10.1002/ijc.2910530115. [DOI] [PubMed] [Google Scholar]
  19. Pera M., Cameron A. J., Trastek V. F., Carpenter H. A., Zinsmeister A. R. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology. 1993 Feb;104(2):510–513. doi: 10.1016/0016-5085(93)90420-h. [DOI] [PubMed] [Google Scholar]
  20. Pierce J. H., Arnstein P., DiMarco E., Artrip J., Kraus M. H., Lonardo F., Di Fiore P. P., Aaronson S. A. Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene. 1991 Jul;6(7):1189–1194. [PubMed] [Google Scholar]
  21. Ramel S., Reid B. J., Sanchez C. A., Blount P. L., Levine D. S., Neshat K., Haggitt R. C., Dean P. J., Thor K., Rabinovitch P. S. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology. 1992 Apr;102(4 Pt 1):1220–1228. [PubMed] [Google Scholar]
  22. Riddell R. H., Goldman H., Ransohoff D. F., Appelman H. D., Fenoglio C. M., Haggitt R. C., Ahren C., Correa P., Hamilton S. R., Morson B. C. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983 Nov;14(11):931–968. doi: 10.1016/s0046-8177(83)80175-0. [DOI] [PubMed] [Google Scholar]
  23. Schechter A. L., Stern D. F., Vaidyanathan L., Decker S. J., Drebin J. A., Greene M. I., Weinberg R. A. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984 Dec 6;312(5994):513–516. doi: 10.1038/312513a0. [DOI] [PubMed] [Google Scholar]
  24. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177–182. doi: 10.1126/science.3798106. [DOI] [PubMed] [Google Scholar]
  25. Spechler S. J. Endoscopic surveillance for patients with Barrett esophagus: does the cancer risk justify the practice? Ann Intern Med. 1987 Jun;106(6):902–904. doi: 10.7326/0003-4819-106-6-902. [DOI] [PubMed] [Google Scholar]
  26. Spechler S. J., Robbins A. H., Rubins H. B., Vincent M. E., Heeren T., Doos W. G., Colton T., Schimmel E. M. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology. 1984 Oct;87(4):927–933. [PubMed] [Google Scholar]
  27. Tytgat G. N., Hameeteman W. The neoplastic potential of columnar-lined (Barrett's) esophagus. World J Surg. 1992 Mar-Apr;16(2):308–312. doi: 10.1007/BF02071538. [DOI] [PubMed] [Google Scholar]
  28. Wen D., Peles E., Cupples R., Suggs S. V., Bacus S. S., Luo Y., Trail G., Hu S., Silbiger S. M., Levy R. B. Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell. 1992 May 1;69(3):559–572. doi: 10.1016/0092-8674(92)90456-m. [DOI] [PubMed] [Google Scholar]
  29. Yokota J., Yamamoto T., Toyoshima K., Terada M., Sugimura T., Battifora H., Cline M. J. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet. 1986 Apr 5;1(8484):765–767. doi: 10.1016/s0140-6736(86)91782-4. [DOI] [PubMed] [Google Scholar]
  30. Yonemura Y., Ninomiya I., Ohoyama S., Kimura H., Yamaguchi A., Fushida S., Kosaka T., Miwa K., Miyazaki I., Endou Y. Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer. 1991 Jun 1;67(11):2914–2918. doi: 10.1002/1097-0142(19910601)67:11<2914::aid-cncr2820671134>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  31. Younes M., Lebovitz R. M., Lechago L. V., Lechago J. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology. 1993 Dec;105(6):1637–1642. doi: 10.1016/0016-5085(93)91058-p. [DOI] [PubMed] [Google Scholar]
  32. al-Kasspooles M., Moore J. H., Orringer M. B., Beer D. G. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer. 1993 May 8;54(2):213–219. doi: 10.1002/ijc.2910540209. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES